{"organizations": [], "uuid": "e6c3b43da689f6bde12ee1875ca5277a0abbf07c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pacira-pharmaceuticals-reports-q4/brief-pacira-pharmaceuticals-reports-q4-gaap-eps-of-0-11-idUSASB0C7ZU", "country": "US", "domain_rank": 408, "title": "BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.763, "site_type": "news", "published": "2018-02-28T21:10:00.000+02:00", "replies_count": 0, "uuid": "e6c3b43da689f6bde12ee1875ca5277a0abbf07c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pacira-pharmaceuticals-reports-q4/brief-pacira-pharmaceuticals-reports-q4-gaap-eps-of-0-11-idUSASB0C7ZU", "ord_in_thread": 0, "title": "BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-pacira pharmaceuticals reports", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "pacira pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Pacira Pharmaceuticals Inc:\n* PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q4 NON-GAAP EARNINGS PER SHARE $0.38\n* Q4 GAAP EARNINGS PER SHARE $0.11 * Q4 REVENUE ROSE 8 PERCENT TO $79.1 MILLION * SEES ‍ 2018 EXPAREL NET PRODUCT SALES OF $300 MILLION TO $310 MILLION​\n* SEES ‍ 2018 NON-GAAP GROSS MARGINS OF 70% TO 72%​\n* SEES ‍ 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE OF $50 MILLION TO $60 MILLION​\n* Q4 EARNINGS PER SHARE VIEW $0.10, REVENUE VIEW $79.3 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T21:10:00.000+02:00", "crawled": "2018-03-01T21:12:37.000+02:00", "highlightTitle": ""}